Daniel Shelly

Moving Beyond CD19 to Identify the Next-Generation of Clinically Viable Targets

With clinical momentum building around CD19-targeted approaches, developers are increasingly exploring novel targets that can address a broader range of indications and enhance safety profiles. Join this interactive workshop to explore emerging approaches for target discovery and the opportunities these targets can enable across autoimmune cell therapy development.

In this workshop, our leaders will be:

• Leveraging AI and computational approaches for identifying novel autoimmune targets
• Establishing preclinical models for validating target selection in autoimmune contexts
• Translating learnings from T-cell engagers and immunology drug development to inform cell therapy target discovery